Patent: 8,906,682
✉ Email this page to a colleague
Summary for Patent: 8,906,682
| Title: | Methods for treatment of cancer |
| Abstract: | The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. |
| Inventor(s): | Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone |
| Assignee: | University of Pennsylvania Penn |
| Application Number: | US13/938,947 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,906,682
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | KYMRIAH | tisagenlecleucel | Injection | 125646 | August 30, 2017 | 8,906,682 | 2033-07-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,906,682
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2011338200 | ⤷ Start Trial |
| Australia | 2017203087 | ⤷ Start Trial |
| Australia | 2017225161 | ⤷ Start Trial |
| Australia | 2020200767 | ⤷ Start Trial |
| Australia | 2022201895 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
